ArticleFrontiers in nutrition2026
The effects of resveratrol on endothelial progenitor cells and apoptosis biomarkers in postmenopausal women with chronic coronary heart disease: a randomized controlled trial.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Menopause is an important cardiovascular risk factor in women likely due to marked estrogen decline. Estrogens affect key processes in atherosclerosis, maintaining endothelial integrity by inhibiting endothelial apoptosis and promoting regeneration through endothelial progenitor cells (EPCs). Phytoestrogens, such as resveratrol, have therapeutic potential for women's cardiovascular health. The present study aimed to determine whether resveratrol modulated circulating apoptosis biomarkers and EPCs in postmenopausal women with chronic coronary heart disease (CHD). Methods: Twenty postmenopausal women with chronic CHD were allocated to an intervention group receiving 1,000 mg of resveratrol or placebo for 90 days. Circulating markers of apoptosis (caspases 3 and 9, survivin, cIAP2, XIAP, Bcl-2, cytochrome c, sTNFR2, and S100A12), SIRT1 and 3, cytokines and EPCs were assessed. Results: At the end of the study, the resveratrol group showed an increase in serum cIAP2 ( Conclusion: Resveratrol increased serum Bcl-2 and cIAP2, and also reduced caspase 9 and circulating EPCs in postmenopausal women with chronic CHD, likely unrelated to circulating SIRT1 and SIRT3. The effects of resveratrol treatment in this population group should be assessed with caution, as a reduction in EPCs is associated with impaired endothelial function and an increased risk of cardiovascular disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.